Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.97 USD | +7.03% | +8.91% | -27.03% |
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-27.03% | 335M | - | ||
+29.68% | 681B | C+ | ||
+19.77% | 556B | B | ||
-4.35% | 361B | C+ | ||
+17.65% | 325B | B- | ||
+3.77% | 285B | C+ | ||
+13.64% | 235B | B+ | ||
+4.37% | 199B | B- | ||
-12.11% | 189B | A+ | ||
-3.79% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- PROC Stock
- Ratings Procaps Group S.A.